Mark Ralph

Mark Ralph was appointed President and Chief Executive Officer of Axine Water Technologies in November 2022, replacing Jonathan Rhone. With over 20 years of experience in the pharmaceutical industry, Mark brings diverse expertise in drug discovery, operations, financial management, business development, licensing, and venture capital.

Mark's academic background comprises an MS degree (Chemistry) from Memorial University (Canada) and an MBA (Finance) from the University of Connecticut. He also holds a BS from Acadia University.

Career History

• President and Chief Executive Officer, Axine Water Technologies (2022–present)
• Executive Director, Boehringer Ingelheim Venture Fund, Boehringer Ingelheim (2020–2022)
• Global Head of Contracts and Alliance Management, US Head of Business Development and Licensing, Boehringer Ingelheim (2016–2020)
• Director, External Partnerships and Financial Strategy, Boehringer Ingelheim (2014–2016)
• Senior Associate Director, External Research Operations, Boehringer Ingelheim (2010–2014)

Ralph has served as a board member for digital health companies including Wellth, xCures, and Optina Diagnostics, and represented Boehringer Ingelheim in a fund-in-fund investment. Axine recently secured investment from Veralto, positioning the company to grow in municipal and industrial markets.

What Mark Ralph could bring to Axine Water Technologies: Mark's 20+ years in pharmaceutical operations, finance, and venture capital position him well to scale Axine's electrochemical oxidation technology across industrial and municipal wastewater markets. His experience in business development, regulatory compliance, and securing strategic partnerships—honed at Boehringer Ingelheim—directly supports Axine's mission to commercialize PFAS treatment solutions and expand into new regulatory environments.